The Annual General Meeting of BioGaia AB on 7 May 2015 voted to approve the
following resolutions:
· adoption of the annual report
· discharge from liability for the Board members and the Managing Director
· a dividend of SEK 5.00 per share
· re-election of Board members Jan Annwall, David Dangoor, Stefan Elving,
Inger Holmström, Brit Stakston and Paula Zeilon
· Election of Anthon Jahreskog and Ewa Björling as Board members
· Anthon Jahreskog, born in 1980, Chief Operating Officer, Fund Linked
Products, Credit Suisse Investment Bank, London. He has several years of
experience from the international financial market and expertise in strategic
business planning, cost efficiency and analysis. Anthon Jahreskog is independent
of the company and its management and does not own any shares in BioGaia. Anthon
Jahreskog does not serve any other boards.
· Ewa Björling, born in 1961, is a trained dentist and a Doctor of Medicine
and senior lecturer in virology with many years of experience from Karolinska
institutet. Ewa Björling has also been a member of the Riksdag and the Minister
for Trade in the Swedish government from 2007 to 2014. Ewa Björling is
independent of the company and its management and does not own any shares in
BioGaia.
· re-election of David Dangoor as Board Chairman
· election of the registered Accounting firm Deloitte AB
· Board member compensation in an amount of SEK 300,000 to the Chairman and
SEK 150,000 to each of the other Board members not employed by the company
· auditors’ fee shall be paid according to approved account
· regarding principles for remuneration and other terms of employment for
senior executives in accordance with the Board’s proposal
· regarding the Nominating Committee in accordance with the Nominating
Committee’s proposal
Item 18 on the agenda, regarding approval of share transfers in Infant Bacterial
Therapeutics AB, was cancelled by the Board of BioGaia.
Latest press releases from BioGaia
2015-05-07 BioGaia AB Interim Management Statement 1 January – 31 March 2015
2015-04-27 Positive results in first Chinese study with BioGaia’s drops in
infants with colic
2015-04-08 Notice to attend the Annual General Meeting of BioGaia AB
BioGaia has published this information in accordance with the Swedish Securities
Market Act. The information was issued for publication on 8 May 2015 8:00 am
CET.
For additional information please contact
Peter Rothschild, Chief Executive Officer, BioGaia: 46 8 555 293 00
BioGaia is a healthcare company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health
-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted
on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com
